Targeting specific genes to improve treatment for head and neck cancer
Official title: Synthetic Lethal Targeting of CREBBP/EP300 in Head and Neck Squamous Cell Carcinoma
Funded at Yale University · NIH-10804966 · Data updated 2026-11-12
This study is looking at how changes in certain genes might help make current cancer treatments work better for people with head and neck cancer, so they can get more effective care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | May 1, 2023 |
| Project end | April 30, 2026 |
| Funding year | 2023 |
| Award (this year) | $563,756 |
| NIH project number | 7R01DE028061-05 |
| Project ID | NIH-10804966 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with head and neck squamous cell carcinoma, particularly those with mutations in the CREBBP or EP300 genes.
✕Less likely to help
Patients with head and neck cancers that do not involve mutations in the CREBBP or EP300 genes may not benefit from this research.
What this research studies
This research investigates how targeting the CREBBP and EP300 genes can enhance the effectiveness of existing DNA-damaging treatments for head and neck squamous cell carcinoma (HNSCC). By using advanced genomic techniques, the study aims to identify how mutations in these genes can make cancer cells more sensitive to therapies like radiation and chemotherapy. The approach involves testing these gene targets in laboratory settings to understand their role in cell death and treatment response. If successful, this could lead to more effective treatment strategies for patients with HNSCC.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment outcomes for patients with head and neck cancer by making existing therapies more effective.
How similar studies have gone: Other research has shown promising results in targeting similar genetic pathways to enhance cancer treatment, indicating that this approach may be viable.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Pickering, Curtis — Yale University
- Study coordinator: Pickering, Curtis
Related research
Other NIH-funded projects on the same topics.
-
Novel idea: Epstein-Barr virus and eye cancer in people living with HIV in Zimbabwe
A study explores whether Epstein-Barr virus could cause a type of eye cancer in people living with HIV in Zimbabwe.
-
Oral cancer recurrence predictor using tumor microbes and gene activity
This NIH grant explores how bacteria and immune signals inside oral cancer tumors relate to whether the cancer comes back, with the aim of making a practical risk predictor for patients.
-
Data-driven classification of aggressive tissue traits to predict cancer outcomes in HPV-negative head and neck cancer
A clinician-science grant uses data science and AI to identify tissue patterns in HPV-negative head and neck cancer that may predict how long patients stay cancer-free.
-
Targeting PIPKIγi5 to boost immune responses against head and neck cancer
A study to see if blocking a specific enzyme, PIPKIγi5, can make head and neck cancer more visible to the immune system and more responsive to existing immunotherapies.
-
Targeted approaches for lung squamous cell carcinoma with key gene changes
A study at a major university is exploring new targets in lung squamous cell carcinoma to help people with this cancer find better treatments.
-
Baculovirus-based therapy to treat head and neck cancer with a gentle, minimally invasive approach
A new, minimally invasive approach using baculovirus-delivered CRISPR gene editing aims to treat head and neck squamous cell carcinoma while aiming to preserve essential tissues.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.